RxDoctor Payments Data

Debbra Forrester

Family · Baker City, ORNPI 1134708753

Payments from drug & device makers

$1,110in general payments, 2019–2025

Across 48 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$201
  • AbbVie$200
  • GSK$164
  • E.r. Squibb & Sons, L.L.C.$126
  • Johnson & Johnson$79
  • Novartis$67
  • plus $274 from 11 others

What the payments were for

  • Food & beverage$1,09499%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,110 in reported general payments places this provider in the 85th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$2,442
Medicare patients
46
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$44,154
OzempicSemaglutide26$30,441
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,069
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$19,017
VraylarCariprazine Hcl12$16,720
Advair HfaFluticasone Propion/Salmeterol17$6,947
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$3,886
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen82$3,317
Fentanyl26$3,078
Levothyroxine Sodium196$2,597
Albuterol Sulfate HfaAlbuterol Sulfate67$2,468
Omeprazole174$2,183
Gabapentin117$2,069
Tamsulosin Hcl59$1,787
SynthroidLevothyroxine Sodium20$1,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$164$45,08668 claims
Novo NordiskOzempic$36$30,44126 claims
AbbVieVraylar, Synthroid$200$18,42332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,130 family providers in Oregon.

Other family in Baker City

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →